The global metered dose inhalers (MDI) market is poised for significant growth, with an estimated market size of USD 26,322.9 million in 2023, up from USD 25,208.9 million in 2022. According to a ...

Asthma Attack Symptoms . Symptoms of an asthma attack may develop gradually or happen suddenly and can vary from person to ...

The increasing demand for asthma treatment is largely driven by the rising number of asthma cases. Factors such as increased smoking and air pollution are impairing lung function and contributing to ...

The global asthma treatment market size was valued at USD 27.51 billion in 2023 and is expected to reach around USD 35.93 billion by 2034. It is growing at a CAGR of 2.42% from 2024 and 2034. The ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

"AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint" was originally created and published by ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

Low climate-impact corticosteroid inhalers are as effective as high climate impact inhalers for COPD and asthma outcomes, per ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in ...

Have you ever thought about breathing in something that could improve your health? It sounds futuristic, but it’s happening ...